PTN - Palatin Technologies

-

$undefined

N/A

(N/A)

Palatin Technologies NYSE American:PTN Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.

Location: Cedar Brook Corporate Center, Cranbury, NJ, 08512, United States | Website: https://palatin.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-611.7K

Cash

3.417M

Avg Qtr Burn

-6.736M

Short % of Float

33.98%

Insider Ownership

2.63%

Institutional Own.

14.22%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Vyleesi® (bremelanotide) MC4r Agonist Details
Sexual dysfunction, Sexual desire disorder, Influenza

Approved

Quarterly sales

PL9643 Details
Dry eye syndrome

Phase 3

Update

Bremelanotide + PDE5i Details
Erectile dysfunction

Phase 2

Data readout

Bremelanotide Details
Diabetic Kidney Disease

Phase 2

Update

PL8177 oral formulation Details
Chronic inflammatory disorder, Inflammatory disease, Bowel disorder, Ulcerative colitis

Phase 2

Update

Bremelanotide + Tirzepatide Details
Obesity, Metabolic disorder

IND

Submission

PL8177 Details
Eye disease , Inflammatory disease

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued